Post EUS/FNA diagnosis showed pseudocyst (46.8%), serous cystadenoma (16.2%), intraductal papillary neoplasm (9%), mucinous cystadenoma (12.6%), neuroendocrine tumour (3.6%), solid pseudopapillary tumour (0.9%) and cystic ductal adenocarcinoma (8.1%). EUS/FNA changed the diagnosis and management in 33.3% (37/111) of the patients. Seventeen patients (45.9%) who were initially diagnosed with benign cyst on imaging had diagnosis changed to malignant/ premalignant

cysts. Only 10 patients underwent surgical resection, 9/10 had malignancy on resection histology. Of the 7 who did not undergo surgery, 4 had metastasis, 2 had premalignant cyst and 1 declined surgery. Twenty (54%) patients who were initially diagnosed with a malignant lesion did not require surgery after EUS/FNA changed the diagnosis. Of these 20, none develop malignant lesion after 6 months of surveillance. The sensitivity and specificity of EUS/FNA and imaging to Selleck AP24534 accurately determine the nature of pancreatic cyst are 75% and 81.1% vs. 25% and 68.4% respectively (P value <0.05). Conclusion: EUS/FNA has valuable role in the management of pancreatic cyst. It is more accurate than imaging alone and can correctly stratify which patients should undergo resection. Key Word(s): 1. Pancreatic cyst; 2. EUS; 3. Imaging; Presenting Author: XIAOYONG WANG Additional Authors: LENING XUE Corresponding

Author: XIAOYONG WANG Affiliations: Changzhou No. 2 Hospital, Affiliated with Nanjing Medical University Objective: Recently, several studies have evaluated the association between hepatitis B virus Talazoparib (HBV) infection and pancreatic cancer risk; however, results have been inconsistent. The goal of this study was to perform a meta-analysis of the published data to evaluate this association. Methods: A search of relevant studies published up to May 2012 was performed. After reviewing each study, extracting data, and evaluating heterogeneity and publication bias, a meta-analysis was performed to evaluate the association of HBV infection and pancreatic cancer risk.

Subgroup analyses were carried out according to the original studies’ designs and separate meta-analyses were performed. Pooled odds ratios (ORs) with 95% confidence intervals MCE (CIs) were calculated using the fixed- or random-effect models. Results: Nine studies, encompassing seven case-control and two cohort studies, were analyzed. Overall, there was an association between hepatitis B surface antigen (HBsAg) -positive carrier state and a higher risk of pancreatic cancer (OR = 1.24, 95% CI: 1.08 to 1.43). Among the case-control studies, the HBsAg carrier state (HBsAg-positive: OR = 1.24, 95% CI: 1.06 to 1.46) and past exposure to HBV without evidence of HBV recovery (HBsAg-negative/anti-HBc-positive/anti-HBs-negative: OR = 1.76, 95% CI: 1.29 to 2.39) were significantly associated with pancreatic cancer risk.